Person:
ÇAMLI, AHMET ADİL

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AHMET ADİL
Last Name
ÇAMLI
Name
Email Address
Birth Date

Filters

Browse subject tree
20142
Reset filters

Settings

Item Type: Publication × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Vaspin and lipocalin-2 levels in severe obsructive sleep apnea.
    (2014-06-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIC, ERDEM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; YAVUZ, E; ARDIC, C; CAMLI, AHMET ADİL; CIKRIKCIOGLU, M; KART, L; KISKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIÇ, ERDEM; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ÇAMLI, AHMET ADİL
    Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS. Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared. Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17). Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.
  • Thumbnail Image
    PublicationOpen Access
    Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
    (2014-01-01) Cakirca, MUSTAFA; Soysal, Pinar; Zorlu, MEHMET; Kiskac, MUHARREM; Kanat, Mustafa; CIKRIKCIOGLU, Mehmet Ali; Karatoprak, CUMALİ; HURSITOGLU, Mehmet; Camli, AHMET ADİL; ERKOC, Reha; ABDUL-GHANI, Muhammad; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; ZORLU, MEHMET; KISKAÇ, MUHARREM; SOYSAL, PINAR; ÇAMLI, AHMET ADİL
    Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.